fluorouracil has been researched along with pyrazines in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Blackey, R; Cassidy, J; Choi, L; Devlin, M; Eatock, M; Johnson, J; Morrison, R; Owen, S; Twelves, C | 1 |
| Kaplow, R | 1 |
| Brossart, P; Freier, W; Greil, R; Kiewe, P; Kühnhardt, D; Kümmel, S; Lange, W; Lehenbauer-Dehm, S; Niederle, N; Possinger, K; Preiss, J; Regierer, A; Schippinger, W; Schmid, P; Van de Velde, H | 1 |
| Beard, M; Cohen, SJ; Engstrom, PF; Langer, CJ; Lewis, NL; McLaughlin, S; Meropol, NJ; Weiner, LM | 1 |
| Broggini, M; Carrassa, L; Crippa, F; Damia, G; Ganzinelli, M; Tavecchio, M | 1 |
| Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C | 1 |
| Begum, NM; Kuribayashi, N; Miyamoto, Y; Nagai, H; Onoue, T; Tamatani, T; Tomizuka, Y; Uchida, D | 1 |
| Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE | 1 |
| Sargent, DJ | 1 |
| Arnold, LA; Atkinson, JM; Boulos, N; Carcaboso, AM; Eden, C; Ellison, DW; Féau, C; Gajjar, A; Gibson, P; Gilbertson, RJ; Guy, RK; Johnson, RA; Koul, D; Kranenburg, TA; Mohankumar, KM; Phoenix, T; Poppleton, H; Priebe, W; Shelat, AA; Stewart, CF; Tong, Y; Wright, K; Yung, WK; Zhu, L | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| Chen, LT; Chen, SH; Chen, TJ; Hsing, CH; Huang, HY; Lee, HH; Lee, SW; Li, CF; Lin, CY; Lin, LC; Pan, HY; Sheu, MJ; Shiue, YL; Tian, YF | 1 |
| Cassidy, J; Hochster, H | 1 |
| Altıkat, S; Boyaci, I; Cavga, FZ; Irmak, R; Kocacan, SA; Yerlikaya, A | 1 |
| Arias, A; Bassi, MR; Meyn, P; Polacek, C; Sempere, RN | 1 |
| Gong, JP; Hu, H; Hu, YB; Li, XL; Mi, YL; Mu, L; Qin, JC; Tao, DD; Wu, YQ; Yan, C; Zhao, H | 1 |
| Dai, X; Liao, Y; Sheng, M; Shi, X; Wu, X | 1 |
2 review(s) available for fluorouracil and pyrazines
| Article | Year |
|---|---|
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
5 trial(s) available for fluorouracil and pyrazines
| Article | Year |
|---|---|
A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Hydroxamic Acids; Leucovorin; Male; Metalloendopeptidases; Middle Aged; Protease Inhibitors; Pyrazines; Rectal Neoplasms; Sulfonamides | 2005 |
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Hematologic Diseases; Humans; Maximum Tolerated Dose; Peripheral Nervous System Diseases; Pyrazines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pyrazines | 2008 |
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Colorectal Neoplasms; Disease-Free Survival; DNA Repair; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Pyrazines; Survival Rate | 2009 |
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Progression; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Pyrazines; Rectal Neoplasms | 2010 |
10 other study(ies) available for fluorouracil and pyrazines
| Article | Year |
|---|---|
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Down-Regulation; Doxorubicin; Etoposide; Female; Fluorescent Antibody Technique; Fluorouracil; Genes, p53; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Protein Kinases; Pyrazines; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays | 2008 |
Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cisplatin; Down-Regulation; Flow Cytometry; Fluorouracil; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Kruppel-Like Transcription Factors; Luciferases; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Pyrazines; Quinolines; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Chemotherapy: Failure of bevacizumab in early-stage colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Failure | 2011 |
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma.
Topics: Animals; Boronic Acids; Bortezomib; Brain; Brain Neoplasms; Cell Proliferation; Centrosome; Drug Screening Assays, Antitumor; Ependymoma; Fluorouracil; High-Throughput Screening Assays; Insulin; Mice; Mice, Nude; Neural Stem Cells; Pyrazines; Signal Transduction; Tumor Cells, Cultured | 2011 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Male; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Pyrazines; Rectal Neoplasms; Retrospective Studies; S-Phase Kinase-Associated Proteins; Survival Rate; Tumor Cells, Cultured | 2013 |
Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; Female; Fluorouracil; Humans; Inhibitory Concentration 50; Pyrazines | 2013 |
Extinction of Zika Virus and Usutu Virus by Lethal Mutagenesis Reveals Different Patterns of Sensitivity to Three Mutagenic Drugs.
Topics: Amides; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Epithelial Cells; Flavivirus; Fluorouracil; Mutagenesis; Mutagens; Mutation Rate; Nucleosides; Pyrazines; Ribavirin; Ribonucleosides; Serial Passage; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection | 2018 |
Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance.
Topics: Animals; Antineoplastic Agents; Cell Dedifferentiation; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Drug Resistance, Neoplasm; Exosomes; Female; Fibroblasts; Fluorouracil; HT29 Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Oxaliplatin; Paracrine Communication; Pyrazines; Pyridines; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |
Investigation on drug entrapment location in liposomes and transfersomes based on molecular dynamics simulation.
Topics: Coumarins; Drug Carriers; Fluorouracil; Liposomes; Molecular Dynamics Simulation; Pyrazines; Solubility | 2021 |